Stockscreener 앱 받기
33.61
0.22%
0.08
전일 마감가:
$33.53
열려 있는:
$34.3
하루 거래량:
62,364
Relative Volume:
0.04
시가총액:
$4.05B
수익:
$10.12M
순이익/손실:
$-280.49M
주가수익비율:
-11.63
EPS:
-2.89
순현금흐름:
$-188.51M
1주 성능:
+0.22%
1개월 성능:
+15.28%
6개월 성능:
+11.53%
1년 성능:
-26.88%
1일 변동 폭
$33.02
$34.51
1주일 범위
$32.81
$35.14
52주 변동 폭
$21.51
$56.00
어비디티 바이오사이언스 Stock (RNA) Company Profile
명칭
Avidity Biosciences Inc
전화
858-401-7900
주소
10578 SCIENCE CENTER DRIVE, SAN DIEGO, CA
RNA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RNA
Avidity Biosciences Inc
|
33.60 | 3.82B | 10.12M | -280.49M | -188.51M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.21 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.03 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.50 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.92 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.56 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
어비디티 바이오사이언스 Stock (RNA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-10 | 재개 | Goldman | Buy |
| 2025-06-24 | 개시 | Bernstein | Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-06-11 | 개시 | Raymond James | Strong Buy |
| 2025-03-13 | 개시 | Citigroup | Buy |
| 2025-03-12 | 개시 | BMO Capital Markets | Outperform |
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-20 | 개시 | H.C. Wainwright | Buy |
| 2024-11-26 | 개시 | RBC Capital Mkts | Outperform |
| 2024-09-24 | 개시 | Goldman | Buy |
| 2024-08-28 | 개시 | Barclays | Overweight |
| 2024-05-03 | 개시 | BofA Securities | Buy |
| 2024-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-05-22 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2023-03-31 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2022-07-20 | 개시 | Chardan Capital Markets | Buy |
| 2022-07-12 | 개시 | Raymond James | Strong Buy |
| 2021-09-07 | 개시 | Evercore ISI | Outperform |
| 2021-06-17 | 개시 | Needham | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | Cowen | Outperform |
| 2020-07-07 | 개시 | Credit Suisse | Outperform |
| 2020-07-07 | 개시 | SVB Leerink | Outperform |
| 2020-07-07 | 개시 | Wells Fargo | Overweight |
모두보기
어비디티 바이오사이언스 주식(RNA)의 최신 뉴스
Avidity gets FDA breakthrough therapy status for DMD treatment - Seeking Alpha
FDA grants breakthrough therapy status to Avidity’s DMD drug By Investing.com - Investing.com Canada
Avidity Biosciences stock rises after FDA grants Breakthrough Therapy status - Investing.com
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping - Yahoo Finance
What analysts say about Avidity Biosciences Inc. stockOutstanding capital appreciation - jammulinksnews.com
What drives Avidity Biosciences Inc. stock priceRobust financial gains - Autocar Professional
Is Avidity Biosciences Inc. a good long term investmentTriple-digit returns - jammulinksnews.com
Avidity Biosciences Inc. Stock Analysis and ForecastExtraordinary market timing - jammulinksnews.com
Why Avidity Biosciences Inc. stock attracts strong analyst attentionCapital Doubling Tips - beatles.ru
(RNA) On The My Stocks Page - news.stocktradersdaily.com
Avidity Biosciences: Three Accelerated Approval Shots Feels Excessive (NASDAQ:RNA) - Seeking Alpha
RNA News Today | Why did Avidity Biosciences stock drop today? - MarketBeat
Goldman Sachs resumes coverage on Avidity Biosciences stock with Buy rating - Investing.com Canada
Avidity Biosciences, Inc Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Avidity Biosciences, Inc Rings the Opening Bell - Nasdaq
Avidity Biosciences’ SWOT analysis: innovative muscle therapy stock faces key milestones - Investing.com
Avidity Biosciences, Inc.(NasdaqGM: RNA) added to Russell 3000E Value Index - MarketScreener
(RNA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Avidity Biosciences’ Promising Phase 3 Study on FSHD Treatment: Market Implications - TipRanks
Avidity Biosciences’ SWOT analysis: innovative RNA firm eyes 3-drug launch by 2027 - Investing.com
Wolfe Research Initiates Coverage on Avidity Biosciences (RNA) with 'Outperform' Rating | RNA Stock News - GuruFocus
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotec - GuruFocus
Why Avidity Biosciences Shares Are Under the Spotlight - TipRanks
Wolfe Research Initiates Coverage on Avidity Biosciences With Outperform Rating, $55 Price Target - MarketScreener
Avidity Biosciences (RNA) Receives Outperform Rating Amid Biotech Advancements | RNA Stock News - GuruFocus
(RNA) Proactive Strategies - news.stocktradersdaily.com
Avidity Biosciences (RNA) Receives Outperform Rating from Wolfe Research | RNA Stock News - GuruFocus
The week in pharma: action, reaction and insight – week to June 13 - The Pharma Letter
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential - Investing.com Australia
Avidity Biosciences’ SWOT analysis: innovative RNA tech targets rare disease stock potential By Investing.com - Investing.com South Africa
Avidity Biosciences chief scientific officer sells $657,694 in stock - Investing.com India
Avidity Biosciences, Inc. (RNA) Initiated with a Strong Buy at Raymond James - MSN
Avidity Biosciences chief scientific officer sells $657,694 in stock By Investing.com - Investing.com South Africa
13 Biotech Stocks with Huge Upside Potential - Insider Monkey
Avidity Biosciences (RNA) Receives Strong Buy Rating from Raymond James | RNA Stock News - GuruFocus
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress – Company AnnouncementFT.com - Financial Times
Avidity's Muscular Dystrophy Drug Del-brax Gets FDA Accelerated Approval Path: Key Data Coming - Stock Titan
Avidity Biosciences holds annual stockholders meeting By Investing.com - Investing.com South Africa
어비디티 바이오사이언스 (RNA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.61%
0.48%
자본화:
|
볼륨(24시간):